Asklepion Pharmaceuticals, LLC – Trademark Portfolio
Entity Type: 16
Asklepion Pharmaceuticals, LLC holds 12 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 10 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include CHOLBAM and ASKLEPION PHARMACEUTICALS. The owner is based in Brentwood, TN.
Suite 204
5200 Maryland Way
Brentwood, TN 37027
Showing of trademarks Trademarks
Trademark Classifications
Asklepion Pharmaceuticals, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Asklepion Pharmaceuticals, LLC have?
Asklepion Pharmaceuticals, LLC has 12 U.S. trademarks filed with the USPTO. Of these, 2 registered, 9 abandoned, 1 cancelled.
What trademark classes does Asklepion Pharmaceuticals, LLC file in?
Asklepion Pharmaceuticals, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Asklepion Pharmaceuticals, LLC's most well-known trademarks?
Asklepion Pharmaceuticals, LLC's registered trademark portfolio includes well-known marks such as CHOLBAM and ASKLEPION PHARMACEUTICALS. These are among 2 currently registered trademarks in the portfolio.
What is Asklepion Pharmaceuticals, LLC's trademark registration success rate?
Asklepion Pharmaceuticals, LLC has a 17% trademark registration rate, with 2 out of 12 resolved applications resulting in successful registration. Currently, 0 applications are pending review.